Anzeige
Mehr »
Dienstag, 12.08.2025 - Börsentäglich über 12.000 News
Diese Aktie liegt in der Turbo-Zone - und könnte der Gold-Gewinner 2025/26 werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JMW5 | ISIN: CA6823108759 | Ticker-Symbol: ONYN
Berlin
12.08.25 | 08:41
0,730 Euro
-0,68 % -0,005
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOLYTICS BIOTECH INC Chart 1 Jahr
5-Tage-Chart
ONCOLYTICS BIOTECH INC 5-Tage-Chart

Aktuelle News zur ONCOLYTICS BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoOncolytics Biotech announces voting results from annual meeting1
MoOncolytics Biotech Inc.: Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders43SAN DIEGO, Aug. 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage...
► Artikel lesen
FrOncolytics Biotech GAAP EPS of -$0.071
ONCOLYTICS BIOTECH Aktie jetzt für 0€ handeln
FrStocks in Play: Oncolytics Biotech Inc-
FrOncolytics Biotech to delist from Toronto Stock Exchange2
FrOncolytics Biotech Inc.: Oncolytics Biotech Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep144Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of...
► Artikel lesen
FrOncolytics Biotech Inc.: Oncolytics Biotech Announces Voluntary Delisting from the Toronto Stock Exchange148SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company...
► Artikel lesen
DoWhat to Expect from Oncolytics Biotech's Earnings1
05.08.ONCOLYTICS BIOTECH INC - 6-K, Report of foreign issuer1
05.08.Oncolytics Biotech Announces Upcoming Annual General Meeting and Second Quarter Financial Results1
29.07.Oncolytics Biotech to engage FDA on potential pancreatic cancer study1
29.07.Oncolytics Biotech im Dialog mit FDA über potenzielle Zulassungsstudie bei Bauchspeicheldrüsenkrebs4
29.07.Oncolytics Biotech sparks FDA discussions for potential pivotal pancreatic cancer trial2
29.07.Oncolytics Biotech Inc.: Oncolytics Biotech to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End101Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accelerated strategy to drive shareholder...
► Artikel lesen
24.07.Stocks in Play: Oncolytics Biotech Inc-
23.07.ONCOLYTICS BIOTECH INC - 6-K, Report of foreign issuer9
22.07.Oncolytics Biotech regains compliance with Nasdaq listing requirements1
22.07.Oncolytics Biotech erfüllt wieder die Notierungsanforderungen der NASDAQ3
22.07.Oncolytics Biotech Inc.: Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules143SAN DIEGO and CALGARY, AB, July 22, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage...
► Artikel lesen
16.07.Stocks in Play: Oncolytics Biotech Inc1
Weiter >>
86 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1